Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 13/2022

15-08-2022 | Dermatofibrosarcoma Protuberans | ASO Author Reflections

ASO Author Reflections: Improving Management Strategies for Patients with Primary Dermatofibrosarcoma Protuberans (DFSP)

Authors: Matthew T. Houdek, MD, Jay S. Wunder, MD

Published in: Annals of Surgical Oncology | Issue 13/2022

Login to get access

Excerpt

Dermatofibrosarcoma protuberans (DFSP), the most common dermal sarcoma, is known to be a locally aggressive and infiltrative tumor.1 Due to its infiltrative nature, microscopically positive margins were historically not recognized during attempts at wide local excision (WLE), leading to high rates of local recurrence. In an attempt to provide real-time margin assessment at the time of resection, Mohs micrographic surgery (MMS) has been increasingly used to reduce the risk of local recurrence.2 Although MMS has been adopted to treat patients with DFSP, it is not available at all centers, evidence on the superiority of MMS over WLE is conflicting.3 …
Literature
1.
Huis In't Veld EA, van Coevorden F, Grunhagen DJ, et al. Outcome after surgical treatment of dermatofibrosarcoma protuberans: Is clinical follow-up always indicated? Cancer. 2019;125:735–41.
2.
van Lee CB, Kan WC, Gran S, et al. Dermatofibrosarcoma protuberans re-excision and recurrence rates in the Netherlands between 1989 and 2016. Acta Derm Venereol. 2019;99:1160–5.PubMed
3.
Huis In't Veld EA, Grunhagen DJ, van Coevorden F, et al. Adequate surgical margins for dermatofibrosarcoma protuberans: a multi-centre analysis. Eur J Surg Oncol. 2021;47:436–42.
4.
5.
Gladdy RA, Wunder JS. Risk-stratified surveillance in dermatofibrosarcoma protuberans: less is more. Cancer. 2019;125(5):670–2.CrossRefPubMed
Metadata
Title
ASO Author Reflections: Improving Management Strategies for Patients with Primary Dermatofibrosarcoma Protuberans (DFSP)
Authors
Matthew T. Houdek, MD
Jay S. Wunder, MD
Publication date
15-08-2022
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 13/2022
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-022-12397-0

Other articles of this Issue 13/2022

Annals of Surgical Oncology 13/2022 Go to the issue

ASO Visual Abstract

ASO Visual Abstract: Clinical, Pathological Complete Response, and Prognosis Characteristics of HER2-Low Breast Cancer in the Neoadjuvant Chemotherapy Setting—A Retrospective Analysis

ASO Visual Abstract

ASO Visual Abstract: Predicting Regional Lymph Node Recurrence in the Modern Age of Tumor-Positive Sentinel Node Melanoma: The Role of the First Postoperative Ultrasound

ASO Author Reflections

ASO Author Reflections: The Role of CEA Optimizing Perioperative Treatments for Colorectal Cancer with Liver Metastases

ASO Author Reflections

ASO Author Reflections: Pretreatment CA 19-9 Threshold of 98 U/mL is a Reasonable Cutoff for Prognostication of Clinical Stage I and II Pancreatic Cancer

Thoracic Oncology

Radiomics with Artificial Intelligence for the Prediction of Early Recurrence in Patients with Clinical Stage IA Lung Cancer

ASO Visual Abstract

ASO Visual Abstract: Pharmacologic Effects of Oxaliplatin Instability in Chloride-Containing Carrier Fluids on the Hyperthermic Intraperitoneal Chemotherapy to Treat Colorectal Cancer In Vitro and In Vivo